<SEC-DOCUMENT>0001493152-24-047085.txt : 20241121
<SEC-HEADER>0001493152-24-047085.hdr.sgml : 20241121
<ACCEPTANCE-DATETIME>20241121092539
ACCESSION NUMBER:		0001493152-24-047085
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		16
CONFORMED PERIOD OF REPORT:	20241118
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20241121
DATE AS OF CHANGE:		20241121

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			GT Biopharma, Inc.
		CENTRAL INDEX KEY:			0000109657
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				941620407
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40023
		FILM NUMBER:		241482368

	BUSINESS ADDRESS:	
		STREET 1:		315 MONTGOMERY STREET
		STREET 2:		10TH FLOOR
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94104
		BUSINESS PHONE:		(800) 304-9888

	MAIL ADDRESS:	
		STREET 1:		315 MONTGOMERY STREET
		STREET 2:		10TH FLOOR
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94104

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	OXIS INTERNATIONAL INC
		DATE OF NAME CHANGE:	19940916

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	DDI PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19920703

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	DIAGNOSTIC DATA INC /DE/
		DATE OF NAME CHANGE:	19850312
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>form8-k.htm
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:us-roles="http://fasb.org/us-roles/2024" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:GTBP="http://gtbiopharma.com/20241118">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02D_US%2DGAAP%2D2024 -->
<!-- Field: Set; Name: xdx; ID: xdx_036_GTBP_gtbiopharma.com_20241118 -->
<!-- Field: Set; Name: xdx; ID: xdx_048_20241118_20241118 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_05D_edei%2D%2DEntityCentralIndexKey_0000109657 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="AsOf2024-11-18" id="Fact000003" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2024-11-18" id="Fact000004" name="dei:EntityCentralIndexKey">0000109657</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="gtbp-20241118.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="AsOf2024-11-18">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-11-18</xbrli:startDate>
        <xbrli:endDate>2024-11-18</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 4pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt">UNITED
STATES<br/>
SECURITIES AND EXCHANGE COMMISSION</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt">Washington,
D.C. 20549</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Rule-Page --><div style="margin: 0pt auto; width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt">FORM
<span id="xdx_909_edei--DocumentType_c20241118__20241118_z4kccFFRLrc6"><ix:nonNumeric contextRef="AsOf2024-11-18" id="Fact000009" name="dei:DocumentType">8-K</ix:nonNumeric></span></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CURRENT
REPORT<br/>
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date
of Report:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Date
of earliest event reported)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="text-decoration: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_edei--DocumentPeriodEndDate_c20241118__20241118_zK6VFkABjrfe"><ix:nonNumeric contextRef="AsOf2024-11-18" format="ixt:datemonthdayyearen" id="Fact000010" name="dei:DocumentPeriodEndDate">November
18, 2024</ix:nonNumeric></span></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Rule-Page --><div style="margin: 0pt auto; width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b><span id="xdx_905_edei--EntityRegistrantName_c20241118__20241118_zYxtv0B0ytlh"><ix:nonNumeric contextRef="AsOf2024-11-18" id="Fact000011" name="dei:EntityRegistrantName">GT
Biopharma, Inc.</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Exact
name of registrant as specified in its charter)</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="text-decoration: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="text-decoration: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_edei--EntityIncorporationStateCountryCode_c20241118__20241118_zx4FtwKA8dQd"><ix:nonNumeric contextRef="AsOf2024-11-18" format="ixt-sec:stateprovnameen" id="Fact000012" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span>(State
or other Jurisdiction</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">of Incorporation)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_900_edei--EntityFileNumber_c20241118__20241118_zTIvIpMnhmZf"><ix:nonNumeric contextRef="AsOf2024-11-18" id="Fact000013" name="dei:EntityFileNumber">1-40023</ix:nonNumeric></span></b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><b><span id="xdx_90F_edei--EntityTaxIdentificationNumber_c20241118__20241118_zoyzI6578sTh"><ix:nonNumeric contextRef="AsOf2024-11-18" id="Fact000014" name="dei:EntityTaxIdentificationNumber">94-1620407</ix:nonNumeric></span></b></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 32%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Commission</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">File Number)</span></p></td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 32%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(IRS
Employer</span></p>
                                                                                <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identification No.)</span></p></td></tr>
</table>

<p style="text-align: center; margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>N/A</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b>(Address of Principal Executive Offices and zip code)</span></p>


<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_901_edei--CityAreaCode_c20241118__20241118_zu5nicPUSb6d"><ix:nonNumeric contextRef="AsOf2024-11-18" id="Fact000015" name="dei:CityAreaCode">(415)</ix:nonNumeric></span>-<span id="xdx_906_edei--LocalPhoneNumber_c20241118__20241118_zFeX67MIcbH9"><ix:nonNumeric contextRef="AsOf2024-11-18" id="Fact000016" name="dei:LocalPhoneNumber">919-4040</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Registrant&#8217;s
telephone number, including area code)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any
of the following provisions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" border="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
  <td style="text-align: justify; width: 0.25in"><span style="font: normal 10pt Times New Roman, Times, Serif"><span id="xdx_900_edei--WrittenCommunications_c20241118__20241118_zOOUW6BCmX27"><ix:nonNumeric contextRef="AsOf2024-11-18" format="ixt:booleanfalse" id="Fact000017" name="dei:WrittenCommunications">&#9744;</ix:nonNumeric></span></span></td>
  <td style="text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">Written communications pursuant to Rule
425 under the Securities Act (17 CFR 230.425)</span></td></tr>

<tr style="vertical-align: top">
  <td style="text-align: justify">&#160;</td>
  <td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
  <td style="text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"><span id="xdx_902_edei--SolicitingMaterial_c20241118__20241118_zIogOEt1l5ef"><ix:nonNumeric contextRef="AsOf2024-11-18" format="ixt:booleanfalse" id="Fact000018" name="dei:SolicitingMaterial">&#9744;</ix:nonNumeric></span></span></td>
  <td style="text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">Soliciting
material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12(b))</span></td></tr>

<tr style="vertical-align: top">
  <td style="text-align: justify">&#160;</td>
  <td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
  <td style="text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"><span id="xdx_900_edei--PreCommencementTenderOffer_c20241118__20241118_zwazTnhVOiTk"><ix:nonNumeric contextRef="AsOf2024-11-18" format="ixt:booleanfalse" id="Fact000019" name="dei:PreCommencementTenderOffer">&#9744;</ix:nonNumeric></span></span></td>
  <td style="text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr>

<tr style="vertical-align: top">
  <td style="text-align: justify">&#160;</td>
  <td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
  <td style="text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"><span id="xdx_90E_edei--PreCommencementIssuerTenderOffer_c20241118__20241118_zpFOTNSquPTh"><ix:nonNumeric contextRef="AsOf2024-11-18" format="ixt:booleanfalse" id="Fact000020" name="dei:PreCommencementIssuerTenderOffer">&#9744;</ix:nonNumeric></span></span></td>
  <td style="text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">Securities
registered pursuant to Section 12(b) of the Act:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 36%; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Title
    of each Class</span></span></td>
    <td style="width: 2%">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 20%; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Trading
    Symbol(s)</span></span></td>
    <td style="width: 2%">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 40%; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Name
    of each Exchange on which registered</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif"><span id="xdx_900_edei--Security12bTitle_c20241118__20241118_zW2UMz7rGyqk"><ix:nonNumeric contextRef="AsOf2024-11-18" id="Fact000021" name="dei:Security12bTitle">Common
    stock, $0.001 par value</ix:nonNumeric></span></span></td>
    <td>&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif"><span id="xdx_903_edei--TradingSymbol_c20241118__20241118_zgicASYmK8y6"><ix:nonNumeric contextRef="AsOf2024-11-18" id="Fact000022" name="dei:TradingSymbol">GTBP</ix:nonNumeric></span></span></td>
    <td>&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif"><span id="xdx_902_edei--SecurityExchangeName_c20241118__20241118_zsNlrUxUrNfc"><ix:nonNumeric contextRef="AsOf2024-11-18" format="ixt-sec:exchnameen" id="Fact000023" name="dei:SecurityExchangeName">The
    Nasdaq Stock Market LLC</ix:nonNumeric></span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><span style="font: normal 10pt Times New Roman, Times, Serif">Emerging
growth company <span id="xdx_90F_edei--EntityEmergingGrowthCompany_c20241118__20241118_zS0dXVUijRDl"><ix:nonNumeric contextRef="AsOf2024-11-18" format="ixt:booleanfalse" id="Fact000024" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"></span></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 4pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
1.01 Entry into a Material Definitive Agreement.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 18, 2024, the Registrant entered into an Investigator Initiated Clinical Trial Agreement (the &#8220;Agreement&#8221;) with
the Regents of the University of Minnesota (the &#8220;University&#8221;), pursuant to which, the University shall sponsor an Investigational
New Drug (&#8220;IND&#8221;) application for IND 165546 GTB-3650 (the &#8220;Research Program&#8221;) and shall serve as a sponsor investigator
for a phase 1 clinical trial entitled, &#8220;GTB-3650 (CD16/IL-15/CD33) Tri-Specific Killer Engager (TriKE) for the Treatment of High
Risk Myelodysplastic Syndromes (MDS), Refractory/Relapsed Acute Myeloid Leukemia (AML), and Minimal Residual Disease in AML,&#8221; designed
by the University (the &#8220;Study&#8221;). The Research Program is being conducted for clinical research use. The budget for the Study,
including without limitations, funding and resources, provides for up to approximately $2 million over the course of three years borne
by the Company. The Study data will be owned by the University, however, the Company may use the Study data subject to any applicable
signed informed consent documents and authorization forms, applicable law and terms of the Agreement. The University and the Company
will each have the right to publish the Study results. The Agreement may be terminated by the Company or the University at any time upon
thirty days&#8217; written notice to the other party, by the University immediately for health, welfare and safety reasons, or by either
party if the other party materially breaches the Agreement, provided that the breaching party fails to cure such breach within thirty
days.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
foregoing description of the Agreement does not purport to be complete and is qualified in its entirety by reference to the full text
of the Agreement attached to this Current Report on Form 8-K as Exhibit 10.1 and incorporated by reference into this Item 1.01.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
9.01 Financial Statements and Exhibits.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
Exhibits</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit
    No.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex10-1.htm">Investigator Initiated Clinical Trial Agreement, dated as of November 18, 2024, by and between GT Biopharma, Inc. and the Regents of the University of Minnesota.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover
    Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*
Certain exhibits and schedules to this exhibit have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The registrant hereby
undertakes to furnish copies of any of the omitted schedules and exhibits upon request by the U.S. Securities and Exchange Commission.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SIGNATURES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 28.35pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" border="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
  <td style="padding-bottom: 1pt; text-align: justify">&#160;</td>
    <td colspan="2" style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GT
BIOPHARMA, INC.</b></span></td></tr>
<tr style="vertical-align: top">
  <td style="padding-bottom: 1pt; text-align: justify">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
  <td style="padding-bottom: 1pt; text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
  <td style="padding-bottom: 1pt; text-align: justify; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: November 21, 2024</span></td>
    <td style="padding-bottom: 1pt; width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
  <td style="border-bottom: Black 1pt solid; text-align: justify; width: 47%"><i>/s/ Alan Urban</i></td></tr>
<tr style="vertical-align: top">
  <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
  <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Alan
Urban</span></td></tr>
<tr style="vertical-align: top">
  <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
  <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
Financial Officer</span></td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left"></p>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjdEKgkAQRb/Afxj2OUy3evExMYksQiJ63XKMJd2R2c3qk/rLNiUaBobh3nOvEBOR00o3yHBalgUcsO0a5RBKrJHRXNA70vUmAX9LvGrrWBk3vD8wJc+gZxahnJ+9MFh7bbFKII6nMprKOUQyWcxgvxXBV0/J1LpC47RqQJkK9kwda3SKX2PCQT3JUPsaqo7IVpPxcWE0ym+QUSxhR716EN8sFEUqgskwgciZ7p13ZU+H5ktC1mDr6+xI/zf4AASXSok= -->
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>ex10-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: (select); font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: (select); font-size: 10pt"><B>EXHIBIT
10.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: (select); font-size: 10pt">&nbsp;</FONT><FONT STYLE="font-family: (select)"><BR STYLE="clear: both"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: (select); font-size: 10pt"><IMG SRC="ex10-1_001.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: (select); font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: (select); font-size: 10pt"><IMG SRC="ex10-1_002.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: (select); font-size: 10pt">Investigator
Initiated Clinical Trial Agreement</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: (select); font-size: 10pt"><B>THIS
INVESTIGATOR INITIATED CLINICAL TRIAL AGREEMENT</B> (this &ldquo;Agreement&rdquo;) is entered into effective as of the date of last signature
(the &ldquo;Effective Date&rdquo;) by and between Regents of the University of Minnesota (the &ldquo;University&rdquo;), a public educational
institution and a Minnesota constitutional corporation, and GT Biopharma, Inc. (the &ldquo;Company&rdquo;), a Delaware corporation. This
Agreement is entered into by the University through its Office of Sponsored Projects Administration. Company and University shall each
be referred to herein, individually, as a &ldquo;Party&rdquo; and collectively as the &ldquo;Parties.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: (select); font-size: 10pt"><B>WHEREAS,
</B>Mark Juckett, MD, is a University employee, and shall act on behalf of University as the sponsor of Investigational New Drug (&ldquo;IND&rdquo;)
application for IND 165546 GTB-3650 (the &ldquo;Research Program&rdquo;) and in performance of the Study as Sponsor Investigator (&ldquo;Sponsor-Investigator&rdquo;)
for a phase 1 clinical trial entitled, &ldquo;GTB-3650 (CD16/IL-15/CD33) Tri-Specific Killer Engager (TriKE) for the Treatment of High
Risk Myelodysplastic Syndromes (MDS), Refractory/Relapsed Acute Myeloid Leukemia (AML), and Minimal Residual Disease in AML,&rdquo; designed
by University (the &ldquo;Study&rdquo;) shown as <B><U>Exhibit A</U></B> to this Agreement and incorporated herein as specified;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: (select); font-size: 10pt"><B>WHEREAS</B>,
the IND is designated as a research IND (non-commercial) involving GTB-3650 (CD16/IL-15/CD33) Tri-Specific Killer Engager (TriKE) (the
&ldquo;Study Drug&rdquo;) and the Study and Study Drug are strictly for clinical research purposes. Neither University nor Dr. Juckett
intend to later commercialize the Study Drug;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: (select); font-size: 10pt"><B>WHEREAS</B>,
the Company is a biopharmaceutical company focused on developing immuno-oncology therapeutic products based on the TriKE protein biologic
technology platform. University and the Company have entered a certain Amended and Restated Exclusive Patent License Agreement dated
May 13, 2024, pursuant to which the Company has an exclusive worldwide license agreement with University to further develop and commercialize
therapies TriKE product candidates;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: (select); font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: (select); font-size: 10pt"><B>WHEREAS</B>,
University has received funding from Company to maintain the Research Program and comply with obligations as the IND sponsor, and to
conduct the Study for clinical research use;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: (select); font-size: 10pt"><B>WHEREAS</B>,
University has appropriate facilities and patient population to provide data for the Study; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: (select); font-size: 10pt"><B>WHEREAS</B>,
the Research Program including the Study contemplated by this Agreement is of mutual interest and benefit to University and to the Company
and will further the instructional and research objectives of University in a manner consistent with its status as nonprofit educational
institution. University and the Company now wish to enter into this Agreement to establish the terms under which the Company will provide
support including, but not limited to, the Study Drug, funding, and reasonable assurances for the Research Program and the Study, and
for Dr. Juckett and University to comply with their Sponsor- Investigator responsibilities;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: (select); font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: NewSection -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: (select)">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: (select); font-size: 10pt"><IMG SRC="ex10-1_001.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: (select); font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: (select); font-size: 10pt"><IMG SRC="ex10-1_002.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt">&nbsp;</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt"><B>NOW,
THEREFORE</B>, the Parties agree as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: (select); font-size: 10pt">1.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt"><U>Sponsor-Investigator</U>.
                                            Sponsor-Investigator shall be considered the sponsor of the Research Program and the Study.
                                            Sponsor-Investigator is responsible for the overall conduct of the Study at the University.
                                            Sponsor-Investigator both initiated and will conduct the Study in accordance with Applicable
                                            Laws (defined below), this Agreement and the Protocol (defined below). If Sponsor-Investigator
                                            is unable to continue to serve in that role and a successor acceptable to both University
                                            and Company is not available, this Agreement may be terminated in accordance with Section
                                            5.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: (select)">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .25in"><FONT STYLE="font-family: (select); font-size: 10pt">2.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt"><U>Compliance
                                            with Laws</U>. Company and University, including their affiliates and contractors, and the
                                            Sponsor-Investigator shall comply with and conduct all aspects of the Research Program and
                                            the Study in compliance with all applicable federal, state, and local laws and regulations,
                                            including the Federal Food, Drug, and Cosmetic Act (FDCA) (21 USC 301 <I>et seq</I>.) and
                                            regulations issued by the U.S. Food and Drug Administration (&ldquo;FDA&rdquo;) including,
                                            but not limited to, 21 CFR Part 312 (Investigational New Drug Application), 21 CFR 50 (Protection
                                            of Human Subjects), 21 CFR 54 (Financial Disclosure by Clinical Investigators), 21 CFR 56
                                            (Institutional Review Boards), regulations pertaining to clinical trials registration and
                                            submission of results provided in 42 CFR 11, and all other generally accepted standards of
                                            good clinical practice as adopted by current FDA regulations and statutes and regulations
                                            of the U.S. Government relating to exportation of technical data, computer software, laboratory
                                            prototypes, and other commodities as applicable to academic institutions (collectively, &ldquo;Applicable
                                            Laws&rdquo;). University and Sponsor-Investigator will only allow individuals who are appropriately
                                            trained and qualified to assist in the Research Program and the conduct and oversight of
                                            the Study.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: (select); font-size: 10pt">3.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt"><U>Study</U>.
                                            University agrees to conduct the Study in accordance with Applicable Laws, this Agreement
                                            and the study protocol (&ldquo;Protocol&rdquo;) which has been written by Sponsor-Investigator
                                            and approved in writing by University and the Company. Sponsor-Investigator shall apply for
                                            approval to conduct the Study with University&rsquo;s Institutional Review Board (&ldquo;IRB&rdquo;)
                                            or an independent Institutional Review Board approved by the University and the Company in
                                            writing. University shall not allow the Study to be initiated until such approval is obtained,
                                            and University and the Company are provided with a final written copy of the IRB approval
                                            letter for the Study. University&rsquo;s right to conduct the Study, including enrollment
                                            of the Study subjects, is expressly conditioned upon the approval of the reviewing IRB. University
                                            shall cooperate with Sponsor-Investigator in preparing and filing the Protocol, informed
                                            consent form, and other required information with the IRB. Changes to the Protocol require
                                            the prior written approval of the IRB. University shall be responsible for obtaining an informed
                                            consent which complies with all Applicable Laws signed by or on behalf of each human subject
                                            prior to the subject&rsquo;s participation in the Study.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .25in"><FONT STYLE="font-family: (select); font-size: 10pt">4.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt"><U>Study
                                            Budget</U>. The Parties agree that Study funding and resources provided by Company shall
                                            be allocated to the Study as outlined in the Budget attached hereto as <B><U>Exhibit B </U></B>and
                                            incorporated herein (the &ldquo;Study Budget&rdquo;). University acknowledges that the Study
                                            Budget represents fair market value for its services in connection with the Study, based
                                            on the research and services provided, and does not take into account in any manner whatsoever
                                            the volume or value of any prescriptions, referrals or business generated among the Parties.
                                            University and Sponsor-Investigator shall not incur additional costs beyond the Study Budget
                                            without first receiving the Company&rsquo;s prior written consent for such increase in expenditure.
                                            All changes to the Study Budget require the Company&rsquo;s prior written approval.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: (select)">&nbsp;</FONT></P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: (select)">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: (select); font-size: 10pt"><IMG SRC="ex10-1_001.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: (select); font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: (select); font-size: 10pt"><IMG SRC="ex10-1_002.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 17.95pt"><FONT STYLE="font-family: (select); font-size: 10pt">5.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt"><U>Term
                                            and Termination</U>.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt">5.1
The term of this Agreement shall commence upon the Effective Date and terminate upon the completion of the Parties&rsquo; Study-related
activities under this Agreement, unless terminated early as further described in this Section 5.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt">5.2.
Either Party has the right to terminate the Study upon thirty (30) days prior written notice to the other Party. The Study may be terminated
immediately upon written notice at any time for any reason by the University or Company when, in its reasonable judgment or that of the
Sponsor- Investigator, the IRB, the FDA or other applicable regulatory authority, it is determined to be inappropriate, impractical,
or inadvisable to continue, in order to protect the Study subjects&rsquo; health, welfare, and safety. If for any reason Sponsor-Investigator
becomes unavailable to direct the performance of the Study under this Agreement, University shall promptly notify Company in writing.
If the Parties are unable to identify a mutually acceptable successor within thirty (30) days following University&rsquo;s notice to
the Company, this Agreement may be terminated by either Party upon thirty (30) days written notice.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt">5.3.
Notwithstanding the above, either Party may, in addition to any other available remedies, terminate this Agreement immediately upon written
notice to the other Party if the other Party materially breaches this Agreement, provided that the breaching Party fails to remedy such
material breach within thirty (30) days after its receipt of written notice thereof; provided, however, that the cure period shall be
suspended during any time that a Party seeks resolution of a dispute as to whether an alleged breach occurred pursuant to any dispute
resolution mechanism under this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt">5.4.
In the event that this Agreement is terminated prior to completion of the Study, for any reason, University shall furnish to Company
any required final report for the Study in a format mutually agreed upon by the Parties. Promptly following any such termination, University
will provide to Company copies of Study Data collected pursuant to the Protocol.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt">5.5.
If this Agreement is terminated early by either Party, University shall be reimbursed for all work completed, on a pro rata basis, and
out-of-pocket, reasonable costs of bringing the Study to termination actually incurred by University through the date of termination,
and for reasonable, non- cancelable commitments actually incurred by University in the performance of the Study through that date as
set forth in the Study Budget. Upon receipt of notice of termination, University will use reasonable efforts to reduce or eliminate further
costs and expenses and will cooperate with Company to provide for an orderly wind-down of the Study. Upon expiration or earlier termination
of this Agreement, University shall return to the Company all unused Study Drug and Company Confidential Information. The following sections
shall survive the expiration or earlier termination of this Agreement: Sections 2, 5.5, 6, 11, 13, 17, 18, 21, 22, 23, 24, 25, 26, 27,
28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 43, 44, </FONT><FONT STYLE="font-family: (select)">45, and 46.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: (select)">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: (select); font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: (select); font-size: 10pt"><IMG SRC="ex10-1_001.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: (select); font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: (select); font-size: 10pt"><IMG SRC="ex10-1_002.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt">&nbsp;</FONT></P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .25in"><FONT STYLE="font-family: (select); font-size: 10pt">6.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt"><U>Study
                                            Drug</U>. Company agrees to provide within a commercially reasonable time period, at no cost
                                            to University, sufficient quantities of the Study Drug to conduct the Study in accordance
                                            with the Protocol. University shall handle, store, and administer or dispense the Study Drug
                                            in accordance with the Protocol, this Agreement, Applicable Laws and the Company&rsquo;s
                                            written instructions for the conduct of the Study. Company and its contractors that perform
                                            drug manufacturing for the Study, are responsible for assuring that the Study Drug is manufactured
                                            in compliance with current good manufacturing practices (21 USC 351(a)(2)(B)) (&ldquo;CGMP&rdquo;).
                                            University shall maintain accurate and complete records of the shipment, delivery, receipt
                                            and disposition of the Study Drug in accordance with the Protocol, this Agreement, Applicable
                                            Laws and the Company&rsquo;s written instructions.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: (select); font-size: 10pt">7.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: (select)"><U>Batch
                                            Documentation</U>. Company shall provide to University the following documents that Company
                                            receives from the supplier of the Study Drug (the &ldquo;Supplier&rdquo;): (a) records that
                                            document the Supplier&rsquo;s steps and processes utilized in the manufacture of the Study
                                            Drug; (b) the documents that are required under the applicable quality technical agreement;
                                            (c) the certificate of analysis for the Study Drug; and <FONT STYLE="font-size: 10pt">(d)
                                            the certificate of compliance for the Study Drug. Upon reasonable written request by University,
                                            Company shall request, and make reasonable efforts to obtain, additional records and documents
                                            from the Supplier to provide further assurance of conformance with CGMP; provided, however,
                                            Company shall not be obligated to provide additional records and documents unless such records
                                            and documents are received from the Supplier.</FONT></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: (select); font-size: 10pt">8.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt"><U>Acceptance
                                            Mechanism</U>. University may reject any quantity of nonconforming Study Drug that has been
                                            delivered to University hereunder by delivering written notice to Company within thirty (30)
                                            days of delivery of such nonconforming Study Drug to Company. Any batch of Study Drug for
                                            which a notice of non-conformance is not delivered within such thirty (30) day period will
                                            be deemed to be accepted by University upon the expiration of such period, provided that
                                            University will have three (3) months from the date that a batch of Study Drug is accepted
                                            to reject the Study Drug by reason of a hidden or latent defect existing at the time of delivery
                                            that was not discoverable upon commercially reasonable physical inspection and testing of
                                            the Study Drug (a &ldquo;Latent Defect&rdquo;), and University must notify Company in writing
                                            of such Latent Defect within three (3) business days of such discovery. However, if the Study
                                            Drug expires prior to the three (3) month period in the foregoing sentence, University will
                                            have until one (1) week prior to the expiration of the Study Drug to reject the Study Drug
                                            because of a Latent Defect. The notice must detail the nature of the Latent Defect, and based
                                            on information reasonably available at the time, how the nonconformance could have resulted
                                            from the Supplier&rsquo;s manufacturing of the Study Drug.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: (select); font-size: 10pt">9.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: (select)"><U>Independent
                                            Testing</U>. If the Supplier does not agree with University&rsquo;s rejection of any Study
                                            Drug as nonconforming Study Drug (as such is communicated to the Supplier by Company on behalf
                                            of University), then the Supplier, Company and University shall engage an independent person
                                            or persons of recognized standing in the industry with respect to the development and CGMP
                                            manufacture of biologic therapeutics, qualified to resolve a dispute between the Supplier,
                                            Company and University, and who is a recognized expert in the field of NK cell biology and
                                            the development of NK cell engagers (a &ldquo;Third Party Expert&rdquo;) to resolve the dispute.
                                            If the dispute concerns the Study Drug&rsquo;s conformance to the specifications or the Supplier&rsquo;s
                                            adherence to the CGMP manufacturing process, the Supplier, Company and University will submit
                                            the master batch records, batch production records, specifications, applicable statement
                                            of work, and other information relevant to the dispute (including a representative sample
                                            of <FONT STYLE="font-size: 10pt">the Study Drug, if necessary) to an independent testing
                                            laboratory mutually agreed to by the Supplier, Company and University. If the dispute concerns
                                            the Supplier&rsquo;s adherence to CGMP, the Supplier, Company and University will submit
                                            the master batch records, batch production records, specifications, applicable statement
                                            of work, and other information relevant to the dispute to a CGMP consultant mutually agreed
                                            to by the Supplier, Company and University. The findings of the Third Party Expert shall
                                            be final and binding on the Supplier, Company and University, absent fraud or manifest error.
                                            In making its determination, the Third Party Expert shall consider the information supplied
                                            by the Supplier, Company and University, the Supplier&rsquo;s acts and omissions, the Company
                                            and University&rsquo;s acts and omissions, and any deficiencies in Company&rsquo;s technology,
                                            components, equipment, raw materials, and the CGMP manufacturing process. The Third Party
                                            Expert shall use the test and analysis methods contained in the CGMP manufacturing process
                                            and the applicable statement of work when conducting their analysis. If the Third Party Expert
                                            determines that the Study Drug was conforming, University shall pay the fees and expenses
                                            of the Third Party Expert. If the Third Party Expert makes any other determination, including,
                                            but not limited to, that the results are inconclusive or that the Study Drug was a non-conforming
                                            batch but not as a result of the Supplier&rsquo;s defective CGMP manufacturing, University
                                            shall pay the fees and expenses of the laboratory or consultant and will have no remedy against
                                            the Supplier or Company for the non-conforming Study Drug.</FONT></FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: (select)">&nbsp;</FONT></P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: (select); font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: (select); font-size: 10pt"><IMG SRC="ex10-1_001.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: (select); font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: (select); font-size: 10pt"><IMG SRC="ex10-1_002.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt">&nbsp;</FONT></P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .25in"><FONT STYLE="font-family: (select); font-size: 10pt">10.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt"><U>Facilities
                                            and Equipment</U>. Company including its affiliates and contractors, shall at its sole cost
                                            and expense, maintain the manufacturing facility and all related quality documentation, processes
                                            and systems used in connection with the Study Drug in compliance with FDA and other CGMP
                                            quality standards and operate in compliance with all applicable environmental, occupational
                                            health and safety laws and regulations. Each Party shall secure and maintain, at its sole
                                            cost and expense, any registrations, approvals, permits, authorizations, and licenses as
                                            are required by Applicable Laws for such Party to perform its obligations under this Agreement.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .25in"><FONT STYLE="font-family: (select); font-size: 10pt">11.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt"><U>Storage</U>.
                                            University shall store and handle all materials and products in accordance with Applicable
                                            Laws, the specifications and quality standards for such Study Drug, including segregating
                                            Study Drug for which final release has not been provided or otherwise not accepted by University.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .25in"><FONT STYLE="font-family: (select); font-size: 10pt">12.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt"><U>Packaging
                                            and Labeling</U>. Company will package and label Study Drug in accordance with the University&rsquo;s
                                            IND, and will comply with all reasonable University instruction regarding the packaging and/or
                                            labeling of Study Drug, including timely updating any such packaging and/or labeling for
                                            the Study Drug. Company will use only University approved packaging and labeling for all
                                            Study Drug delivered hereunder and shall not modify any packaging or labeling for any such
                                            Study Drugs without University&rsquo;s prior written consent.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: (select)">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .25in"><FONT STYLE="font-family: (select); font-size: 10pt">13.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt"><U>Qualified
                                            Personnel</U>. University and Sponsor-Investigator shall only assign personnel who are trained,
                                            qualified, and experienced to perform the Study, and University and Sponsor-Investigator
                                            shall ensure that all personnel assisting with the performance of the Study comply with all
                                            provisions of this Agreement, including by requiring personnel to sign intellectual property
                                            assignment and confidentiality and nondisclosure agreements sufficient to enable University
                                            and Sponsor-Investigator to comply with their obligations under this Agreement.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: (select)">&nbsp;</FONT></P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: (select); font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: (select); font-size: 10pt"><IMG SRC="ex10-1_001.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: (select); font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: (select); font-size: 10pt"><IMG SRC="ex10-1_002.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt">&nbsp;</FONT></P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .25in"><FONT STYLE="font-family: (select); font-size: 10pt">14.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt"><U>Change
                                            Control</U>. If either Party desires to implement a change to the manufacturing process,
                                            including any testing method with respect to any Study Drug or any specifications, or if
                                            University is required by FDA or any other governmental authority to implement any such change,
                                            the Parties will discuss in good faith the potential effect on the identity, strength, quality,
                                            purity, or potency of the Study Drug, and will agree in writing prior to the implementation
                                            of any such change to the manufacturing process. Unless agreed upon by the Parties in writing,
                                            Company has no obligation to provide new Study Drug incorporating any change of the manufacturing
                                            process.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: (select)">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .25in"><FONT STYLE="font-family: (select); font-size: 10pt">15.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt"><U>Deviations
                                            and Nonconformances</U>. Deviations and nonconformances including OOS results and unexplained
                                            discrepancies shall be investigated and documented and retained as part of the batch documentation
                                            for the batch of Study Drug affected according to the applicable written procedures. Company
                                            shall notify University in writing promptly of any deviation or nonconformance, where such
                                            finding is classified as serious or critical based on the risk of potential adverse impact
                                            on Study Drug quality and patient safety, but no longer than one (1) business day after Company&rsquo;s
                                            knowledge of the event, including insofar as the Company determines the Study Drug is subject
                                            to such deviations or nonconformances, including OOS results, after delivery to University.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt">Company
shall investigate all such deviations and nonconformances, and shall timely take corrective action to avoid future occurrences. Company
shall use commercially reasonable efforts to complete its investigation of any deviations and nonconformances including confirmed OOS
results within thirty (30) days of commencement, and will maintain a written justification where such investigation requires a longer
period of time to complete.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .25in"><FONT STYLE="font-family: (select); font-size: 10pt">16.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt"><U>Nonconforming
                                            Drug</U>. Subject to Sections 8, 9, and 15 above, if either Party becomes aware that any
                                            batch or shipment of Study Drug does not conform to the approved specifications for Study
                                            Drug, such Party shall notify the other Party in writing as soon as reasonably practicable
                                            but in no event later than three (3) business days of becoming aware of such nonconformance.
                                            Any batch or shipment of nonconforming Study Drug shall be handled as follows: (a) any such
                                            Study Drugs held in inventory by Company shall not be shipped; and (b) any previously shipped
                                            nonconforming Study Drug held in stock by either Party or its affiliate shall be segregated
                                            and maintained in a &ldquo;hold&rdquo; or &ldquo;quarantine&rdquo; status, and in the case
                                            of each of clauses (a) and (b), such Study Drugs shall not be released or further distributed
                                            until the Parties have completed any investigations related to such nonconforming Study Drug.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .25in"><FONT STYLE="font-family: (select); font-size: 10pt">17.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt"><U>Retention
                                            Samples</U>. Company shall ensure adequate representative samples are retained for each batch
                                            or lot of Study Drug and of delivered materials used in manufacturing, packaging, and labeling
                                            the Study Drug to enable subsequent testing of such Study Drug, in accordance with the University&rsquo;s
                                            IND and University&rsquo;s instruction. Company shall accurately label such samples to identify
                                            the batch of Study Drug and shall store all such samples as appropriate in accordance with
                                            the applicable specifications. Company shall retain all samples of the Study Drug or materials
                                            and intermediates therein for the longer of (a) one (1) year following the indicated expiry
                                            date of such Study Drug and (b) such longer period of time as may be required by Applicable
                                            Laws.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: (select)">&nbsp;</FONT></P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: (select); font-size: 10pt"><IMG SRC="ex10-1_001.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: (select); font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: (select); font-size: 10pt"><IMG SRC="ex10-1_002.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt">&nbsp;</FONT></P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .25in"><FONT STYLE="font-family: (select); font-size: 10pt">18.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt"><U>Stability
                                            Testing</U>. Company will maintain, retain, and store sufficient retention samples of Study
                                            Drug as necessary to perform applicable stability tests in conformance with CGMP and as required
                                            by FDA or any other governmental authority, in accordance with the specifications for such
                                            Study Drug and this Agreement. Retention samples shall be retained for the longer of (a)
                                            the expiry date of the applicable Study Drug plus one (1) year, or (b) such longer period
                                            of time as may be required by Applicable Laws.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: (select); font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: (select); font-size: 10pt">19.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt"><U>Complaints
                                            and Adverse Events</U>. As between the Parties, Company including its affiliates and contractors
                                            engaged in manufacturing the Study Drug, shall establish and maintain guidelines and procedures
                                            for the receipt, investigation, recordation, communication, and exchange (as between the
                                            Parties) around product quality complaints or adverse events and any other information concerning
                                            the quality or safety of the Study Drug. Each Party shall immediately notify the other Party
                                            of any product complaints or adverse events received by such Party concerning any Study Drug
                                            supplied hereunder. Company shall investigate all such complaints and adverse events and,
                                            where necessary and appropriate, shall take corrective action to avoid future occurrences.
                                            The Parties shall investigate any reports of nonconforming Study Drug or any other product
                                            complaint or adverse events in order to assess, as applicable, the potential risk of impact
                                            to the relevant Study Drugs and to determine the validity of such product complaint or adverse
                                            event. Company shall notify University immediately of any difficulty in manufacturing, packaging,
                                            labeling, or delivery any Study Drug in accordance with their applicable specifications,
                                            Applicable Laws, or the terms and conditions of this Agreement. University may, at its option,
                                            investigate the cause of any failure itself. Company will complete any quality investigation
                                            according to established written procedures, and shall provide University with a written
                                            report summarizing the results of Company&rsquo;s investigation. Company shall cooperate
                                            with University in handling such nonconforming products, complaints, or adverse events, and
                                            shall take reasonable actions and provide any additional assistance and information as University
                                            reasonably requests, including promptly investigating and conducting any follow-up with regard
                                            to such nonconforming products, product complaints, or adverse events, and providing any
                                            data, information, or other assistance that University may reasonably require in connection
                                            therewith.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: (select)">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .25in"><FONT STYLE="font-family: (select); font-size: 10pt">20.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt"><U>Recovery
                                            or Withdrawal</U>. Company shall keep University informed of any notification or other information,
                                            whether received directly or indirectly, which might affect the safety or effectiveness of
                                            any Study Drug or which might result in product recovery or withdrawal in connection with
                                            the Study Drug. If either Party in good faith determines that a product recovery or field
                                            action involving any Study Drug is warranted, such Party shall immediately notify the other
                                            Party and shall advise such other Party of the reasons underlying its determination that
                                            such product recovery or withdrawal if warranted; provided, however, that University shall
                                            retain full authority and responsibility for instituting any recovery or field action of
                                            any Study Drug and corresponding with the applicable governmental authorities. Company will
                                            cooperate with University in connection with any such recovery or withdrawal, and promptly
                                            provide to University, any data, information, or assistance as reasonably requested by University
                                            in connection therewith.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: (select); font-size: 10pt">21.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt"><U>Safety
                                            Reporting and Monitoring</U>.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt">21.1
Safety Reporting. University and Sponsor-Investigator shall be solely responsible for reporting all adverse events occurring in connection
with the Study to FDA. University and Sponsor- Investigator shall contact Company immediately in writing, and in no event later than
five (5) business days, to report any serious adverse drug experience or unexpected adverse drug experience, as defined at 21 CFR 312.32.
University and Sponsor-Investigator shall respond promptly to all requests for follow- up information from Company. Company shall respond
promptly to all requests for follow-up information from University and Sponsor-Investigator. University and Sponsor-Investigator shall
inform the IRB of any adverse drug experiences, in accordance with the policies and procedures of the IRB.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: (select); font-size: 10pt"><IMG SRC="ex10-1_001.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: (select); font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: (select); font-size: 10pt"><IMG SRC="ex10-1_002.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt">&nbsp;</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt">21.2
Study Monitoring. University and Sponsor-Investigator shall be responsible for monitoring and quality assurance of all data and information
set forth in Section 22 below in compliance with 21 CFR Part 312.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: (select); font-size: 10pt">22.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt"><U>Study
                                            Data and Results</U>.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.3in"><FONT STYLE="font-family: (select); font-size: 10pt">22.1</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt">University
                                            will provide progress reports to Company at least quarterly and updates following the completion
                                            of each Study subject&rsquo;s dose regimen in accordance with the Protocol. Within one (1)
                                            year of the conclusion or termination of the Study, University will submit a final Study
                                            report to the Company, which will include a clean limited data set in the format set forth
                                            in Exhibit C (&ldquo;Limited Data Set&rdquo;). Nothing herein shall authorize the Company
                                            to use or further disclose the Limited Data Set in a manner that would violate the requirements
                                            of University under 45 CFR 164.514. Company shall not use or further disclose the Limited
                                            Data Set other than as permitted by this Agreement or as otherwise required by law. Company
                                            shall report to the University any use or disclosure of the Limited Data Set not provided
                                            for by this Agreement within 5 business days of when it becomes aware of such use or disclosure.
                                            Company will not use the Limited Data Set, either alone or in concert with any other information,
                                            to make any effort to identify or contact individuals who are or may be the sources of Limited
                                            Data Set without specific written approval from University and appropriate Institutional
                                            Review Board approval, if required pursuant to 45 CFR 46. Should Company inadvertently receive
                                            identifiable information or otherwise identify a Study subject, Company shall promptly notify
                                            University and follow University&rsquo;s reasonable written instructions, which may include
                                            return or destruction of the identifiable information.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.3in"><FONT STYLE="font-family: (select); font-size: 10pt">22.2</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt">All
                                            data and information generated in performance of the Study (&ldquo;Study Data&rdquo;) shall
                                            be the sole property of University. University and Sponsor-Investigator each hereby grant
                                            to Company a perpetual, irrevocable, non-exclusive, worldwide, royalty-free, fully sublicensable
                                            license to exploit the Study Data, progress reports and the final report prepared for Company
                                            for any purpose subject to any applicable signed informed consent documents and authorization
                                            forms, Applicable Laws and terms of this Agreement.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.3in"><FONT STYLE="font-family: (select); font-size: 10pt">22.3</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt">Notwithstanding
                                            anything to the contrary in this Agreement, upon reasonable request, University will provide
                                            Company with any information related to the Study that is necessary for Company to determine
                                            whether to pursue commercial development of GTB-3650 through a separate IND application for
                                            Company&rsquo;s Phase II trial.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: (select)">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: (select); font-size: 10pt">23.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: (select)"><U>HIPAA</U>.
                                            The Parties understand and agree that any use of disclosure of Protected Healthcare Information,
                                            as defined in the Health Insurance Portability and Accountability Act of 1996 and its implementing
                                            regulations (&ldquo;HIPAA&rdquo;) shall be subject to the authorization provided by the Study
                                            subject in the informed consent or other authorization document. In addition, University
                                            shall collect, use, store and disclose data <FONT STYLE="font-size: 10pt">and materials,
                                            including any biological safety samples, collected from Study subjects only as allowed by
                                            the informed consents, or other authorizations, obtained from such Study subjects. University
                                            shall maintain Study records for the period of time and in a secure fashion as required by
                                            applicable Good Clinical Practices, federal, state, local laws, and regulations, including
                                            HIPAA.</FONT></FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: (select)">&nbsp;</FONT></P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: (select); font-size: 10pt"><IMG SRC="ex10-1_001.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: (select); font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: (select); font-size: 10pt"><IMG SRC="ex10-1_002.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt">&nbsp;</FONT></P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: (select); font-size: 10pt">24.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt"><U>Publications</U>.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: (select)">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt">24.1
Company recognizes that under University policy the results of the Study must be publishable and agrees that researchers engaged in the
Study shall be permitted to present at symposia, national or regional professional meetings and to publish in journals, theses or dissertations,
or otherwise of their own choosing, methods and results of the Study (each, a &ldquo;Publication&rdquo;). University shall have the final
authority to determine the scope and content of any University Publication; provided, however, that University shall provide copies of
any proposed Publication at least thirty (30) days in advance of the Publication to Company to review and object to such Publication
because such draft either contains information deemed to be Confidential Information under the provisions of Section 27 of this Agreement,
or reveals information that if published within thirty (30) days would have an adverse effect on a patent application in which Company
owns full or part interest, or intends to obtain an interest from University pursuant to this Agreement. In the event that Company notifies
the University in writing that the proposed Publication contains Company&rsquo;s Confidential Information, the University shall remove
any Company Confidential Information from the draft prior to such Publication. In the event Company requests in writing a delay in Publication
to file for patent protection, the University and the Sponsor- Investigator shall refrain from making such Publication for a maximum
of ninety (90) days from the receipt of such objection, and Company shall indicate with specificity to what manner and degree University
may disclose said information during the ninety (90) day period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt">24.2
Company shall have the right to make Publications and issue press releases regarding the Study and the Study results (each, a &ldquo;Company
Publication&rdquo;). Company shall have the final authority to determine the scope and content of any Company Publication; provided,
however, that Company shall provide copies of any proposed Company Publication that includes the results of the Study at least thirty
</FONT><FONT STYLE="font-family: (select)">(30) days in advance of the Company Publication to University to review and object to such
Company Publication because such draft either contains information deemed to be Confidential Information under the provisions of Section
27 of this Agreement, or reveals information that if published within thirty (30) days would have an adverse effect on a patent application
in which University owns full or part interest. In the event that University notifies the Company in writing that the proposed Company
Publication contains University&rsquo;s Confidential Information, the Company shall remove any University Confidential Information from
the draft prior to such Company Publication. In the event University requests in writing a delay in the proposed Company Publication
to file for patent protection, the Company shall refrain from making such Company Publication for a maximum of ninety (90) days from
the receipt of such objection, and University shall indicate with specificity to what manner and degree Company may disclose said information
during the ninety (90) day period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt">24.3
Publication by either Party to this Agreement shall give proper credit to the other Party for the cooperative character of the Study;
provided that, for any such Company Publication, Company shall obtain prior written approval pursuant to Section 35 below, to use the
name, logos and other marks and trade names of University, or of any individual member of University staff, including Sponsor- Investigator
and University personnel involved with the Research Program. For clarity, and notwithstanding the foregoing, Company may, without prior
written approval of the University, state in a Publication in a factual, non-misleading manner that the Study is being conducted at the
University.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: (select); font-size: 10pt"><IMG SRC="ex10-1_001.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: (select); font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: (select); font-size: 10pt"><IMG SRC="ex10-1_002.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt">&nbsp;</FONT></P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: (select); font-size: 10pt">25.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt"><U>Inspection</U>.
                                            University shall notify Company in writing (including via electronic mail) of any proposed
                                            visit or inspection by any governmental authority if such visit or inspection has the potential
                                            to impact the Study. University shall in good faith cooperate with the governmental authority
                                            in the conduct of such inspection and provide such access to any locations, personnel or
                                            records as requested by such governmental authority. University shall provide Company with
                                            summaries of all reports, documents or correspondence with respect to any governmental authority
                                            requests or inspections of the facility related to the Study, as well as a copy of each such
                                            report, document or correspondence, which copies shall be provided promptly to Company. Company
                                            will be provided an opportunity to review and provide comments to any regulatory correspondence
                                            or other request, and University will provide Company with any proposed corrective actions,
                                            responses and other changes arising out of such review or inspection by such governmental
                                            authority. University shall cause Sponsor-Investigator and its permitted subcontractors to
                                            comply with this Section 25.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: (select)">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: (select); font-size: 10pt">26.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt"><U>Documentation</U>.
                                            University shall maintain complete, legible, and accurate Study records as required by Applicable
                                            Laws and Company&rsquo;s instruction. Upon and in accordance with Company&rsquo;s request,
                                            University shall provide Company with complete, legible, and accurate copies of any such
                                            requested Study records. Without limiting the foregoing, Study records shall be available
                                            at all reasonable times for review and inspection by Company for verification of compliance
                                            with this Agreement. Prior to destroying any such Study records, University shall provide
                                            Company with at least thirty (30) days written notice, and upon Company&rsquo;s request within
                                            such thirty (30) day period, shall cooperate with Company to transfer over any Study records
                                            to Company or its designee in accordance with Company&rsquo;s instructions and at Company&rsquo;s
                                            reasonable and documented expense.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .25in"><FONT STYLE="font-family: (select); font-size: 10pt">27.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt"><U>Confidentiality</U>.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt">27.1
For purposes of this Agreement, &ldquo;Confidential Information&rdquo; means written or tangible information disclosed by or on behalf
of either Party (the &ldquo;Disclosing Party&rdquo;) to the other Party (the &ldquo;Receiving Party&rdquo;) or its Representatives (including
Sponsor-Investigator), which at the time of disclosure is clearly and conspicuously labeled &ldquo;Confidential&rdquo; or &ldquo;Proprietary&rdquo;.
Confidential Information shall also include oral and visual disclosures which are identified as confidential at the time of such disclosures
and which are confirmed and summarized within fifteen (15) days of the disclosure by the Disclosing Party in a writing that sets forth
the substance of the Confidential Information disclosed. Notwithstanding the foregoing, information disclosed by the Disclosing Party
pursuant to this Agreement that is not identified as &ldquo;Confidential&rdquo; or &ldquo;Proprietary&rdquo; will nevertheless be treated
as Confidential Information by the Receiving Party if a reasonable person knowledgeable in the industry and field would, based upon the
nature of the information or the circumstances surrounding its disclosure, consider such disclosure to be confidential and/or proprietary.
The Protocol shall be considered University&rsquo;s Confidential Information regardless of being labeled as such. The Parties agree to
maintain confidentiality of the Confidential Information during the term of this Agreement, including any renewal periods, and for a
period of three (3) years from the effective termination or expiration date of this Agreement (except for trade secrets, which shall
be held in confidence for so long as they are protected under applicable law). Neither Party shall use said Confidential Information
for any purpose other than those purposes specified in this Agreement. The Parties may disclose Confidential Information to their officers,
directors, employees, agents and representatives (collectively, &ldquo;Representatives&rdquo;) requiring access thereto for the purposes
of this Agreement provided, however, that prior to making any such disclosures each such Representative shall be apprised of the duty
and obligation to maintain Confidential Information in confidence and not to use such information for any purpose other than in accordance
with the terms and conditions of this Agreement and shall be bound in writing by obligations of confidentiality and non-use at least
as stringent as the obligations set forth herein. Each Party shall be responsible for any breach of this Section 27 by its Representatives.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: (select); font-size: 10pt"><IMG SRC="ex10-1_001.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: (select); font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: (select); font-size: 10pt"><IMG SRC="ex10-1_002.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt">&nbsp;</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt">27.2
Nothing contained herein will in any way restrict or impair either Party&rsquo;s right to use, disclose, or otherwise deal with any Confidential
Information which the Receiving Party can demonstrate through written documentation:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt">27.2.1
At the time of its receipt, is generally available in the public domain, or thereafter becomes available to the public through no act
of the Receiving Party;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt">27.2.2
Was independently known prior to receipt thereof, or made available to such Receiving Party as a matter of lawful right by a third party;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt">27.2.3
Is received without obligation of confidentiality from a third party; or</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt">27.2.4
Is developed independently by the Receiving Party without use of or reference to the Confidential Information of the Disclosing Party.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt">In
the event that a Party is required by law (including the Minnesota Government Data Practices Act), and/or regulation or court order to
disclose Confidential Information, the Party required to make such disclosure shall notify the other Party in writing to allow that Party
to assert whatever exclusions or exemptions may be available to it under law. In the event that a protective order or other appropriate
remedy is not obtained by the Disclosing Party, the Receiving Party shall only furnish that portion of the Confidential Information that
is legally required to be disclosed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .25in"><FONT STYLE="font-family: (select); font-size: 10pt">28.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt"><U>Intellectual
                                            Property.</U></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt">28.1
It is recognized and understood that certain existing inventions and technologies are the separate property of University or Company
and are not affected by this Agreement, and neither Party shall have any claims or rights in such separate inventions. University agrees
that any new patentable inventions, developments, or discoveries resulting from the Study (&ldquo;Inventions&rdquo;) shall be promptly
disclosed in writing to Company. Any Inventions developed in the course of the Study conducted hereunder shall be owned by the Party
whose Representatives make or generate the Invention, in accordance with the Parties&rsquo; respective intellectual property policies
and procedures. Jointly made or generated Inventions shall be jointly owned by the Parties. In all cases, inventorship shall be determined
in accordance with United States patent law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: (select)">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"></P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: (select); font-size: 10pt"><IMG SRC="ex10-1_001.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: (select); font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: (select); font-size: 10pt"><IMG SRC="ex10-1_002.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt">&nbsp;</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt">28.2
Company is hereby granted, without option fee other than consideration of the Study sponsored herein and the reimbursement to University
for patent expenses incurred prior to or during the option period, an option to acquire an exclusive, worldwide, royalty bearing license
to any Invention owned by University (&ldquo;University Inventions&rdquo;), which option shall extend for no more than ninety (90) days
after Company&rsquo;s receipt of an Invention disclosure from University in writing (&ldquo;Option Period&rdquo;). The Parties shall
use their reasonable efforts to negotiate in good faith, for a period not to exceed ninety (90) days after Company&rsquo;s exercise of
such option, a license agreement reasonably satisfactory to both Parties (&ldquo;Negotiation Period&rdquo;). In the event Company fails
to exercise its option within the Option Period, or the Parties fail to reach agreement on the terms of such license within the Negotiation
Period, University shall have no further obligation to Company under this Agreement with regard to such Invention.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt">28.3
Regardless of whether Company acquires a license to a University Invention, University retains an irrevocable, world-wide, royalty-free,
non-exclusive right to use the University Inventions for non-commercial teaching, research and educational purposes. The University shall
have the right to sublicense its rights under this section to one or more non-profit academic or research institutions for non-commercial
purposes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .25in"><FONT STYLE="font-family: (select); font-size: 10pt">29.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt"><U>Insurance
                                            and Indemnification.</U></FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: (select)">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt">29.1
Each Party represents that it has and will continue to have at least the following levels of insurance or self-insurance during the term
of this Agreement: (i) as to the University, Workers&rsquo; Compensation in statutory compliance with Minnesota State Law; and (ii) as
to both Parties, General Liability Insurance in an amount not less than one million dollars ($1,000,000) each claim/three million dollars
($3,000,000) each occurrence. University represents that the University and Sponsor- Investigator have and will continue to have Professional
Liability insurance in an amount not less than one million dollars ($1,000,000) each claim/three million dollars ($3,000,000) each occurrence.
Company represents that it has and will continue to have Study Drug Liability insurance or self-insurance in an amount not less than
one million dollars ($1,000,000) per claim/three million dollars ($3,000,000) per occurrence. Certificates of all insurance detailed
above shall be furnished to the other Party upon request.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt">29.2
Each Party shall be responsible for its own acts and the results thereof and not for the acts of the other Party. Liability of the University
is subject to the terms and limitations of the Minnesota Tort Claims Act, Minnesota Statutes Section 3.736.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt">29.3
Company shall indemnify, defend, and hold harmless University against any and all third party claims, costs, or liabilities, including
attorneys&rsquo; fees and court costs at both trial and appellate levels (collectively, &ldquo;Claims&rdquo;), to the extent arising
from (a) a material breach of this Agreement by Company, </FONT><FONT STYLE="font-family: (select)">(b) the gross negligence or willful
misconduct of Company, or (c) a violation of law by Company in connection with Company&rsquo;s performance under this Agreement. Section
29.3 shall apply with the provision that (a) University promptly notifies Company in writing after University receives notice of any
<FONT STYLE="font-size: 10pt">Claim and (b) University reasonably cooperates with Company in the defense of any such Claim. Notwithstanding
the foregoing, Company shall not settle or dispose of any such Claim in any manner which would adversely affect the rights or interests
of University without the prior written consent of University, or make any admission of guilt or negligence of University without University&rsquo;s
prior written consent, which shall not be unreasonably withheld, conditioned or delayed.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: (select); font-size: 10pt"><IMG SRC="ex10-1_001.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: (select); font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: (select); font-size: 10pt"><IMG SRC="ex10-1_002.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt">&nbsp;</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt">29.4
Subject to the terms and limits of the Tort Claims Act, Minnesota Statutes Section 3.736, University shall indemnify, defend, and hold
harmless Company against any and all Claims to the extent arising from (a) a material breach of this Agreement by University or Sponsor-Investigator,
(b) the gross negligence or willful misconduct of University, Sponsor-Investigator or their Representatives, or (c) a violation of law
by University, Sponsor-Investigator or their Representatives in connection with University and/or Sponsor-Investigator&rsquo;s performance
under this Agreement. Section 29.4 shall apply with the provision that (a) Company promptly notifies University in writing after Company
receives notice of any Claim and (b) Company reasonably cooperates with University in the defense of any such Claim. Notwithstanding
the foregoing, University shall not settle or dispose of any such Claim in any manner which would adversely affect the rights or interests
of Company without the prior written consent of Company, or make any admission of guilt or negligence of Company without Company&rsquo;s
prior written consent, which shall not be unreasonably withheld, conditioned or delayed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .25in"><FONT STYLE="font-family: (select); font-size: 10pt">30.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt"><U>Reimbursement</U>.
                                            If a Study subject suffers an adverse reaction, medical illness, or injury which was directly
                                            caused by a Study Drug that was properly administered in accordance with the Protocol and
                                            this Agreement, Company shall reimburse University for the reasonable and necessary expenses
                                            that are actually incurred in the diagnosis and treatment of any Study subject injury (not
                                            covered by 3rd party payers such as Medicare or privacy insurance), including hospitalization,
                                            but only to the extent such adverse reaction, medical illness or injury are not caused by
                                            (i) University&rsquo;s, Sponsor-Investigator&rsquo;s or the Study subjects&rsquo; negligence
                                            or willful misconduct; (ii) the natural progression of an underlying or pre- existing condition
                                            or events, unless exacerbated by participating in the Study; or (iii) University&rsquo;s
                                            and/or Sponsor-Investigator&rsquo;s failure to adhere to and comply with the specifications
                                            of the Protocol and all reasonable written instructions furnished by Company for the use
                                            and administration of any Study Drug used in the Study, provided that deviations from the
                                            Protocol and written instructions resulting from an imminent threat to the health or safety
                                            of a Study subject that does not cause the injury to the Study subject will not disqualify
                                            University from reimbursement under this provision.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .25in"><FONT STYLE="font-family: (select); font-size: 10pt">31.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt"><U>Disclaimer
                                            of Warranties.</U> Except for Sections 1, 6, 10, and 12 above, neither Party makes any warranties,
                                            express or implied, as to any matter whatsoever, including without limitation, the condition,
                                            originality or accuracy of the research or any invention (s) or product(s), whether tangible
                                            or intangible, conceived, discovered, or developed under this Agreement; or the ownership,
                                            merchantability, or fitness for a particular purpose of the research or any such invention
                                            or product. COMPANY MAKES NO REPRESENTATIONS AND EXTENDS NO WARRANTIES OF ANY KIND, EITHER
                                            EXPRESS OR IMPLIED, WITH RESPECT TO THE STUDY DRUG. THE STUDY DRUG IS PROVIDED &ldquo;AS-IS&rdquo;.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: (select)">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: (select); font-size: 10pt">32.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt"><U>LIMITATION
                                            OF LIABILITY.</U> IN NO EVENT SHALL EITHER PARTY&rsquo;S LIABILITY TO THE OTHER PARTY INCLUDE
                                            DAMAGES FOR WORK STOPPAGE, LOST DATA, OR INDIRECT, SPECIAL OR CONSEQUENTIAL DAMAGES (INCLUDING
                                            LOST PROFIT) OF ANY KIND. EXCEPT FOR EACH PARTY&rsquo;S OBLIGATIONS UNDER SECTIONS 29.3,
                                            29.4, AND 30, NO PARTY&rsquo;S LIABILITY TO THE OTHER PARTY UNDER THIS AGREEMENT SHALL EXCEED
                                            THE MONETARY CONSIDERATION DUE OR PAYABLE TO THE UNIVERSITY UNDER THIS AGREEMENT.</FONT></TD></TR></TABLE>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt"><BR STYLE="clear: both"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: (select); font-size: 10pt"><IMG SRC="ex10-1_001.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: (select); font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: (select); font-size: 10pt"><IMG SRC="ex10-1_002.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt">&nbsp;</FONT></P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: (select); font-size: 10pt">33.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt"><U>Debarment.
                                            </U>Each Party represents and warrants that neither it nor any of its or its affiliates&rsquo;
                                            employees or agents performing under this Agreement has ever been, or is currently: (a) debarred
                                            under 21 USC 335a or by any regulatory authority; (b) excluded, debarred, suspended, or otherwise
                                            ineligible to participate in federal health care programs or in federal procurement or non-procurement
                                            programs; (c) listed on the FDA&rsquo;s Disqualified and Restricted Lists for clinical investigators;
                                            or (d) convicted of a criminal offense that falls within the scope of 42 USC 1320a-7(a),
                                            but has not yet been excluded, debarred, suspended, or otherwise declared ineligible. Each
                                            Party further covenants that if, during the term of this Agreement, it becomes aware that
                                            it or any of its or its affiliates&rsquo; employees or agents performing under this Agreement
                                            is the subject of any investigation or proceeding that could lead to that Party becoming
                                            a debarred entity or individual, an excluded entity or individual or a convicted entity or
                                            individual, in each case pursuant to subsections (a) through (d) of this section, such Party
                                            will promptly notify the other Party in writing. Each Party further covenants that if, during
                                            the term of this Agreement, it becomes aware that it or any of its or its affiliates&rsquo;
                                            employees or agents is the subject of any investigation or proceeding that could lead to
                                            that entity becoming a debarred entity or individual, an excluded entity or individual or
                                            a convicted entity or individual, in each case pursuant to subsections (a) through (d) of
                                            this section, such Party will promptly notify the other Party in writing.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: (select); font-size: 10pt">34.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt"><U>Export
                                            Controls</U>. The Parties acknowledge that their activities may be subject to export control
                                            laws and regulations, including, without limitation, the Export Administration Regulations
                                            (15 CFR Parts 730-774) (&ldquo;EAR&rdquo;), the International Traffic in Arms Regulations
                                            (22 CFR Parts 120-130) (&ldquo;ITAR&rdquo;), and the Foreign Assets Control Regulations (31
                                            CFR Parts 501-598). Except as provided in the following paragraph, each Party will be solely
                                            responsible for its compliance with such export control laws and regulations. Before transferring
                                            any commodity, software, or technical data (collectively, &ldquo;Items&rdquo;) subject to
                                            the EAR or ITAR to University, Company must first give notice to University that it intends
                                            to transfer the Items in question. Such notice shall identify the relevant classification
                                            on the Commerce Control List (for EAR Items) or category of the U.S. Munitions List (for
                                            ITAR Items). University shall have the right to decline receipt of Items subject to the EAR
                                            or ITAR. Company shall not transfer Items subject to the EAR or ITAR to University until
                                            University has furnished written confirmation that it (a) will accept the Items, and (b)
                                            either has implemented a technology control plan or has determined that one is not needed.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .25in"><FONT STYLE="font-family: (select); font-size: 10pt">35.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt"><U>Publicity</U>.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt">35.1
Company will not use the name, logos and other marks and trade names of University, nor of any individual member of University staff,
including Sponsor-Investigator and University personnel involved with the Research Program, in any publicity, advertising, or news release
without the prior written approval of an authorized representative of University, except where required by law. University will not use
the name, logos and other marks and trade names of Company, nor any Representative of Company, in any publicity, advertising, or news
release without the prior written approval of Company. For clarity, and notwithstanding the foregoing, Company may, without prior written
approval of the University, state in a Publication in a factual, non-misleading manner that the Study is being conducted at the University.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"></P>

<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: (select); font-size: 10pt"><IMG SRC="ex10-1_001.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: (select); font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: (select); font-size: 10pt"><IMG SRC="ex10-1_002.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt">&nbsp;</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt">35.2
Pursuant to the University&rsquo;s Openness in Research Policy (a copy of which may be found at http://www1.umn.edu/regents/policies/academic/Openness_in_Research.pdf)
the University shall be allowed to disclose the following non-confidential information without the approval of the Company: (1) the existence
of the contract or grant; (2) the identity of the Company or the grantor and, if a subcontract is involved, the identity of the prime
contractor if the results of the research must be reported to the sponsor, grantor, or prime contractor; and (3) the purpose and the
scope of the proposed research. The University may also disclose information as needed to comply with institutional reporting requirements,
conflict of interest reviews, or in sponsored projects proposals or award documents (e.g., list of current and pending support.).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt">35.3
In accordance with the rules and regulations of the U.S. Securities Exchange Commission and other reporting requirements for publicly
listed companies, Company may disclose the following non- confidential information in any such disclosures without the written approval
of the University: (1) the existence of this Agreement; (2) the identity of the University and, if a subcontract is involved, the identity
of the prime contractor; and (3) the purpose and the scope of the Research Program. For clarity, Company may also disclose any such information
as needed to comply with U.S. Government reporting requirements or other such reporting requirements in accordance with Applicable Laws
governing the Parties and research performed under the terms of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt">35.4
Each Party represents, warrants, and covenants that it will avoid deceptive, misleading or unethical practices and it will make no false
or misleading statements regarding the Product or the Study (or the results thereof).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: (select); font-size: 10pt">36.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt"><U>Modification</U>.
                                            Any alteration, modification, or amendment to this Agreement must be in writing and signed
                                            by both Parties. No changes in the Protocol will be made unless agreed upon by University,
                                            the Sponsor-Investigator and the Company in writing and approved by the IRB, or if it is
                                            necessary to protect the safety, rights, or welfare of the Study subjects. Any such changes
                                            must be fully, accurately, and contemporaneously documented in accordance with established
                                            procedures. University shall, within one (1) business day from occurrence, or as otherwise
                                            specified in the Protocol, notify Company in writing of any change from the Protocol, including
                                            any change necessary to protect the safety, rights, or welfare of the Study subjects.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .25in"><FONT STYLE="font-family: (select); font-size: 10pt">37.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt"><U>Survival
                                            of Regulatory Obligations</U>. All regulatory obligations contained herein that are required
                                            of either Party or both Parties by an applicable governmental authority with respect to the
                                            Study shall survive termination of this Agreement and for the period of time required by
                                            Applicable Laws.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: (select)">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .25in"><FONT STYLE="font-family: (select); font-size: 10pt">38.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt"><U>Assignment</U>.
                                            This Agreement may not be assigned by either Party without the prior written consent of the
                                            other Party; provided, however, that either Party may assign this Agreement without the other
                                            Party&rsquo;s written consent to an affiliate or in connection with a change of control,
                                            merger, acquisition, or sale of all or substantially all of its business or assets to which
                                            this Agreement relates. University may subcontract with subsites with the prior written consent
                                            of the Company and will execute a written agreement with subsites obligating them to comply
                                            with relevant terms and conditions of this Agreement.</FONT></TD></TR></TABLE>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: (select)">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: (select); font-size: 10pt"><IMG SRC="ex10-1_001.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: (select); font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: (select); font-size: 10pt"><IMG SRC="ex10-1_002.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt">&nbsp;</FONT></P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .25in"><FONT STYLE="font-family: (select); font-size: 10pt">39.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt"><U>Independent
                                            Contractor.</U> University&rsquo;s relationship to Company under this Agreement shall be
                                            that of an independent contractor and not an agent, joint venturer, or partner of University.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .25in"><FONT STYLE="font-family: (select); font-size: 10pt">40.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt"><U>Notice</U>.
                                            Notices, requests, invoices, or communications, hereunder shall be deemed made upon submission
                                            to an overnight courier service or priority United States Mail, or three days after mailing
                                            by United States, first-class mail, certified or registered, postage prepaid, and addressed
                                            to the party to receive such notice, invoice, or communication at the address given below,
                                            or such other address as may hereafter be designated by notice in writing:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: (select); font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="width: 3%"><FONT STYLE="font-family: (select)">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 47%"><FONT STYLE="font-family: (select); font-size: 10pt">If to Company:</FONT></TD>
    <TD STYLE="width: 2%"><FONT STYLE="font-family: (select)">&nbsp;</FONT></TD>
    <TD STYLE="width: 10%"><FONT STYLE="font-family: (select)">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 38%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt">GT
                                            Biopharma, Inc. </FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD><FONT STYLE="font-family: (select)">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: (select)">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: (select)">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: (select)">Address:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: (select)">315
                                            Montgomery Street</FONT></P>
                                                         <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: (select)">9th
                                            &amp; 10th Floors</FONT></P>
                                                         <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: (select)">San
                                            Francisco, CA 94104</FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD><FONT STYLE="font-family: (select)">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: (select)">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: (select)">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: (select)">Telephone:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: (select); font-size: 10pt">(650) 808-7394</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD><FONT STYLE="font-family: (select)">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: (select)">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: (select)">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: (select)">E-Mail:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: (select)"><U>mb@gtbiopharma.com</U></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD><FONT STYLE="font-family: (select)">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: (select)">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: (select)">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: (select)">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: (select)">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD><FONT STYLE="font-family: (select)">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: (select); font-size: 10pt">If to University: (Insert
    Name)</FONT></TD>
    <TD><FONT STYLE="font-family: (select)">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: (select)">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -48.8pt"></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt">Sponsored
    Projects Administration</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt">University
    of Minnesota</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt">450
    McNamara Alumni Center</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt">200
    Oak Street S.E.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt">Minneapolis,
    MN 55455-2070</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt">Telephone:
    (612)</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt">Fax
    : (612)</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: (select); font-size: 10pt">E-Mail: @umn.edu</FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD><FONT STYLE="font-family: (select)">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: (select)">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: (select)">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: (select)">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: (select)">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD><FONT STYLE="font-family: (select)">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: (select); font-size: 10pt">with a copy to Sponsor-Investigator
    (Insert Contact Information)</FONT></TD>
    <TD><FONT STYLE="font-family: (select)">&nbsp;</FONT></TD>
    <TD><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: (select)">Name:</FONT></P>
        <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: (select)">Address:</FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt">Mark
                                            Juckett, M.D.,</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt">Department
    of Medicine</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt">Hematology,
    Oncology, Transplantation</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt">420
    Delaware St SE</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt">Minneapolis,
    MN 55455</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD><FONT STYLE="font-family: (select)">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: (select)">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: (select)">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: (select)">E-Mail:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: (select)"><U>juck0001@umn.edu</U></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .25in"><FONT STYLE="font-family: (select); font-size: 10pt">41.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt"><U>Entire
                                            Agreement</U>. This Agreement and its attached Exhibits represent the entire understanding
                                            between the Parties, and supersedes all other agreements, express or implied, between the
                                            Parties as to its subject matter. Any alteration, modification, or amendment to this Agreement
                                            must be in writing and signed by both Parties. In the event of conflict between the terms
                                            of the Protocol and this Agreement, the terms of the Protocol shall govern all medical and
                                            scientific matters, and the terms of this Agreement shall govern all other matters.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: (select)">&nbsp;</FONT></P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: (select); font-size: 10pt"><IMG SRC="ex10-1_001.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: (select); font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: (select); font-size: 10pt"><IMG SRC="ex10-1_002.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt">&nbsp;</FONT></P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .25in"><FONT STYLE="font-family: (select); font-size: 10pt">42.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt"><U>Force
                                            Majeure</U>. If either Party hereto shall be delayed or hindered in, or prevented from, the
                                            performance of any act required hereunder for any reason beyond such Party&rsquo;s reasonable
                                            control, including but not limited to, strike, lockouts, labor troubles, governmental or
                                            judicial actions or orders, riots, insurrections, war, acts of God, inclement weather or
                                            other reason beyond the Party&rsquo;s reasonable control (a &ldquo;Disability&rdquo;) then
                                            such Party&rsquo;s performance shall be excused for the period of the Disability. Any Study
                                            timelines affected by a Disability shall be extended for a period equal to the delay and
                                            any affected Study Budget shall be adjusted to account for cost increases or decreases resulting
                                            from the Disability as mutually agreed by the Parties in writing. The Party affected by the
                                            Disability shall promptly notify the other Party of such Disability in writing as provided
                                            for herein. Subject to Section 5 above, tn the event that a Disability shall occur and be
                                            continuing for a period in excess of sixty (60) days, either Party may terminate this Agreement
                                            upon written notice to the other Party.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .25in"><FONT STYLE="font-family: (select); font-size: 10pt">43.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt"><U>Execution</U>.
                                            This Agreement may be signed in counterpart by the Parties and the Sponsor-Investigator,
                                            and together shall serve as the final, agreed-upon representation of their respective assent
                                            to its terms. Each Party and the Sponsor-Investigator may execute this Agreement in portable
                                            document format, which shall constitute their assent to its terms.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .25in"><FONT STYLE="font-family: (select); font-size: 10pt">44.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt"><U>Governing
                                            Law; Venue</U>. This Agreement shall be governed and construed in accordance with the laws
                                            of the State of Minnesota, without regard to any conflicts of laws principles that would
                                            require interpretation under the laws of any other jurisdiction. Any action brought under
                                            this Agreement shall only be brought in the courts located of Hennepin County, Minnesota,
                                            USA.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .25in"><FONT STYLE="font-family: (select); font-size: 10pt">45.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt"><U>Equitable
                                            Relief</U>. Each Party agrees that any breach or threatened breach of Section 27 of this
                                            Agreement may result in significant and irreparable damage to a Party, and such Party shall
                                            be entitled, in addition to any other remedies available at law or in equity, to seek injunctive
                                            or other equitable relief by a court of appropriate jurisdiction.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .25in"><FONT STYLE="font-family: (select); font-size: 10pt">46.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt"><U>Waiver;
                                            Severability</U>. The failure to enforce any right or provision herein shall not constitute
                                            a waiver of that right or provision. No waiver of any breach, right, or obligation under
                                            this Agreement shall be effective unless in writing and signed by the Party to be charged.
                                            No consent to or waiver of a breach by either Party hereto, whether express or implied, shall
                                            constitute a consent to, waiver of, or excuse for any other, different, or subsequent breach
                                            by such Party. Any of the provisions of this Agreement which are determined to be invalid
                                            or unenforceable in any jurisdiction shall be ineffective to the extent of such invalidity
                                            or unenforceability in such jurisdiction, without rendering invalid or unenforceable the
                                            remaining provisions hereof or affecting the validity or enforceability of any of the provisions
                                            of this Agreement in any other jurisdiction.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: (select); font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: (select); font-size: 10pt"><B><U>[REMAINDER
OF PAGE INTENTIONALLY LEFT BLANK]</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: (select); font-size: 10pt"><B>&nbsp;</B></FONT></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 17 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt"><BR STYLE="clear: both"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: (select); font-size: 10pt"><IMG SRC="ex10-1_001.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: (select); font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: (select); font-size: 10pt"><IMG SRC="ex10-1_002.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt">&nbsp;</FONT></P>


<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt"><B>IN
WITNESS WHEREOF</B>, the undersigned have executed this Agreement as of the Effective Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: (select); font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 49%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt"><B>REGENTS
                                            OF THE</B></FONT></P>
                                                                                                     <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt"><B>UNIVERSITY
                                            OF MINNESOTA</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt"><B>&nbsp;</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt"><B>&nbsp;</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P></TD>
    <TD STYLE="width: 2%"><FONT STYLE="font-family: (select)">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 49%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt"><B>GT
                                            BIOPHARMA, INC</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt"><B>&nbsp;</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: (select); font-size: 10pt">Name:</FONT></TD>
    <TD><FONT STYLE="font-family: (select)">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: (select); font-size: 10pt">Name:</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: (select)">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: (select)">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: (select)">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: (select); font-size: 10pt">Title:</FONT></TD>
    <TD><FONT STYLE="font-family: (select)">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: (select); font-size: 10pt">Title:</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: (select)">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: (select)">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: (select)">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: (select); font-size: 10pt">Date:</FONT></TD>
    <TD><FONT STYLE="font-family: (select)">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: (select); font-size: 10pt">Date:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt">I
have read the above agreement and agree to perform my obligations as Sponsor-Investigator under this Agreement. I also understand and
agree to the disposition of rights in inventions, discoveries, and other results as provided by this Agreement and to the provisions
concerning confidentiality and Publications. I will inform students and other participants working on the Study of their rights and obligations
under this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt">Sponsor-Investigator</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: (select)">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: (select)">&nbsp;</FONT></TD>
  <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: (select)">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="padding-bottom: 1pt; width: 5%"><FONT STYLE="font-family: (select); font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; width: 45%"><FONT STYLE="font-family: (select)">&nbsp;</FONT></TD>
  <TD STYLE="padding-bottom: 1pt; width: 50%"><FONT STYLE="font-family: (select)">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: (select)">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: (select)">&nbsp;</FONT></TD>
  <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: (select)">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD><FONT STYLE="font-family: (select); font-size: 10pt">Title:</FONT></TD>
    <TD><FONT STYLE="font-family: (select)">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: (select)">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD><FONT STYLE="font-family: (select)">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: (select)">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: (select)">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD><FONT STYLE="font-family: (select); font-size: 10pt">Date:</FONT></TD>
    <TD><FONT STYLE="font-family: (select)">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: (select)">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt">&nbsp;<BR STYLE="clear: both"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt"><B>EXHIBIT
A - PROTOCOL</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt"><B>EXHIBIT
B &ndash; STUDY BUDGET</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt"><B>EXHIBIT
C &ndash; DATA REPORT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: (select); font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<!-- Field: Page; Sequence: 18; Options: Last -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: (select); font-size: 10pt"><B>&nbsp;</B></FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ex10-1_001.jpg
<TEXT>
begin 644 ex10-1_001.jpg
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MT]35UM?8V=KAXN/DY>;GZ.GJ\?+S]/7V]_CY^O_$ !\!  ,! 0$! 0$! 0$
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M_BB)Y--G61HWD7 W?,J,!O 94.T[AVX)Q6Y0 4444 1RRK#$\KY(12Q"@DX
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M<'85X!//%<R(+P:;/I/ANPLW6T>1AIU];"4P';)+*ZQ$Q,!*V%0*" 7Z #
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3>BB@#1HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>ex10-1_002.jpg
<TEXT>
begin 644 ex10-1_002.jpg
M_]C_X  02D9)1@ ! @$ 2 !(  #_X@Q824-#7U!23T9)3$4  0$   Q(3&EN
M;P(0  !M;G1R4D="(%A96B 'S@ "  D !@ Q  !A8W-P35-&5     !)14,@
M<U)'0@                  ]M8  0    #3+4A0("
M                                             !%C<')T   !4
M #-D97-C   !A    &QW='!T   !\    !1B:W!T   "!    !1R6%E:   "
M&    !1G6%E:   "+    !1B6%E:   "0    !1D;6YD   "5    '!D;61D
M   "Q    (AV=65D   #3    (9V:65W   #U    "1L=6UI   #^    !1M
M96%S   $#    "1T96-H   $,     QR5%)#   $/   " QG5%)#   $/
M" QB5%)#   $/   " QT97AT     $-O<'ER:6=H=" H8RD@,3DY."!(97=L
M971T+5!A8VMA<F0@0V]M<&%N>0  9&5S8P         2<U)'0B!)14,V,3DV
M-BTR+C$              !)S4D="($E%0S8Q.38V+3(N,0
M                                                    6%E:(
M     /-1  $    !%LQ865H@                     %A96B        !O
MH@  ./4   .06%E:(        &*9  "WA0  &-I865H@        )*    ^$
M  "VSV1E<V,         %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M    %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M                                  !D97-C         "Y)14,@-C$Y
M-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M     "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M
M('-21T(                             9&5S8P         L4F5F97)E
M;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
M    +%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR
M+C$                                  '9I97<      !.D_@ 47RX
M$,\4  /MS  $$PL  UR>     5A96B       $P)5@!0    5Q_G;65A<P
M       !                         H\    "<VEG(     !#4E0@8W5R
M=@        0     !0 *  \ %  9 !X (P H "T ,@ W #L 0 !% $H 3P!4
M %D 7@!C &@ ;0!R '< ? "! (8 BP"0 )4 F@"? *0 J0"N +( MP"\ ,$
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M])5?E<F6-):?EPJ7=9?@F$R8N)DDF9"9_)IHFM6;0INOG!R<B9SWG62=TIY
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M]XKX&?BH^3CYQ_I7^N?[=_P'_)C]*?VZ_DO^W/]M____[@ .061O8F4 9
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MQ\C)RM+3U-76U]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_:  P#   !$0(1 #\
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M,O\ D>=+_P!^?_T1+110!IZI_P E,T__ +#P_P#2^2N[^+O_ ")DO_7U;_\
MH5%% #_A+_R)5M_UWN?_ $8:\PD_Y'C7?IXD_P#2:]HHH Z#2?\ DB^J?]??
*_M6VKS:BB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>gtbp-20241118.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.24b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 96Mps7xRiXgen8uDanwsWa6O+bP9z5Z8CekhvWB2bQkqfyIj+yW+6SpTOj9mIZQC -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:srt-types="http://fasb.org/srt-types/2024" xmlns:GTBP="http://gtbiopharma.com/20241118" elementFormDefault="qualified" targetNamespace="http://gtbiopharma.com/20241118">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://gtbiopharma.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="gtbp-20241118_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="gtbp-20241118_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" />
    <import namespace="http://fasb.org/us-gaap/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" />
    <import namespace="http://fasb.org/us-types/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2024" schemaLocation="https://xbrl.sec.gov/country/2024/country-2024.xsd" />
    <import namespace="http://fasb.org/srt/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd" />
    <import namespace="http://fasb.org/srt-types/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>gtbp-20241118_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.24b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>gtbp-20241118_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.24b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://gtbiopharma.com/role/Cover" xlink:href="gtbp-20241118.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ErrCompDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#AwardTimingDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingArrangements" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingPoliciesProc" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" />
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" />
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" />
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" />
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" />
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" />
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" />
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46815865993824">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Nov. 18, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Nov. 18,  2024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">1-40023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">GT
Biopharma, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000109657<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">94-1620407<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(415)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">919-4040<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common
    stock, $0.001 par value<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">GTBP<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>10
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MPNZ_/[&\UDX:?^:+X3]>?P%02P$"% ,4    "  R2W59!T%-8H$   "Q
M$               @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    (
M #)+=5FI!$5X[@   "L"   1              "  :\   !D;V-0<F]P<R]C
M;W)E+GAM;%!+ 0(4 Q0    ( #)+=5F97)PC$ 8  )PG   3
M  "  <P!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ ,DMU6=J7
M7&G0 P  ]@T  !@              ("!#0@  'AL+W=O<FMS:&5E=',O<VAE
M970Q+GAM;%!+ 0(4 Q0    ( #)+=5F?H!OPL0(  .(,   -
M  "  1,,  !X;"]S='EL97,N>&UL4$L! A0#%     @ ,DMU69>*NQS
M$P(   L              ( ![PX  %]R96QS+RYR96QS4$L! A0#%     @
M,DMU6:K$(A8S 0  (@(   \              ( !V \  'AL+W=O<FMB;V]K
M+GAM;%!+ 0(4 Q0    ( #)+=5DD'INBK0   /@!   :              "
M 3@1  !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( #)+
M=5EED'F2&0$  ,\#   3              "  1T2  !;0V]N=&5N=%]4>7!E
<<UTN>&UL4$L%!@     )  D /@(  &<3      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>18</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="form8-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="form8-k.htm">form8-k.htm</File>
    <File>gtbp-20241118.xsd</File>
    <File>gtbp-20241118_lab.xml</File>
    <File>gtbp-20241118_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="18">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>17
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "form8-k.htm": {
   "nsprefix": "GTBP",
   "nsuri": "http://gtbiopharma.com/20241118",
   "dts": {
    "inline": {
     "local": [
      "form8-k.htm"
     ]
    },
    "schema": {
     "local": [
      "gtbp-20241118.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "gtbp-20241118_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "gtbp-20241118_pre.xml"
     ]
    }
   },
   "keyStandard": 18,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2024": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 59,
   "unitCount": 3,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2024": 18
   },
   "report": {
    "R1": {
     "role": "http://gtbiopharma.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "AsOf2024-11-18",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form8-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-11-18",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form8-k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CountryRegion",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Extension",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12gTitle",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>18
<FILENAME>0001493152-24-047085-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001493152-24-047085-xbrl.zip
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MM KRZ4.S .3%T:2S<DHMTR>>H0G!8N[+CM9,']ED=]YA6M\6@8@0]!=R%\L
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M07'#)L1DW6*,*0/C[7_M^WM[>_C/-A=@4'3[!=?\-#Z]N;'UOPX;'T\'Y%/
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MC#2.00 ]MXXQ+G^NN[%A>087\M98$CE2S7MCMUHPW>5G>B)0NIY.;P@BEXM
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MJK!E*+U.X([+D=U-35.RW#7AI%7,AA] 3AFWH6CZB8J'BQIP)ZET>20J5.Q
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MU[*J#VJB_,>XD?O>+58JK<N6<[WG<R37<<P)_M^7 VO__P%02P,$%     @
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MN4B(.9+.^\@^]K$^SM_/8QX\4J69%!>UYM%Q+: BE!$3XXO:ET&]/>CT>K5
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M'7L5_P<;]>UMC-OR\GJUO^PFY>;(/U!+ 0(4 Q0    ( #)+=5DH(P3:&%P
M  Z; @ *              "  0    !E>#$P+3$N:'1M4$L! A0#%     @
M,DMU6=-$1FE(%0  !H@   L              ( !0%P  &9O<FTX+6LN:'1M
M4$L! A0#%     @ ,DMU62EY_^PP P  [ L  !$              ( !L7$
M &=T8G M,C R-#$Q,3@N>'-D4$L! A0#%     @ ,DMU614#OCK^"@  @(8
M !4              ( !$'4  &=T8G M,C R-#$Q,3A?;&%B+GAM;%!+ 0(4
M Q0    ( #)+=5F3BK#3W0<  /9>   5              "  4&   !G=&)P
G+3(P,C0Q,3$X7W!R92YX;6Q02P4&      4 !0 V 0  48@

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>form8-k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="gtbp-20241118.xsd" xlink:type="simple"/>
    <context id="AsOf2024-11-18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
        </entity>
        <period>
            <startDate>2024-11-18</startDate>
            <endDate>2024-11-18</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:AmendmentFlag contextRef="AsOf2024-11-18" id="Fact000003">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="AsOf2024-11-18" id="Fact000004">0000109657</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="AsOf2024-11-18" id="Fact000009">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="AsOf2024-11-18" id="Fact000010">2024-11-18</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="AsOf2024-11-18" id="Fact000011">GT Biopharma, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="AsOf2024-11-18" id="Fact000012">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="AsOf2024-11-18" id="Fact000013">1-40023</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="AsOf2024-11-18" id="Fact000014">94-1620407</dei:EntityTaxIdentificationNumber>
    <dei:CityAreaCode contextRef="AsOf2024-11-18" id="Fact000015">(415)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="AsOf2024-11-18" id="Fact000016">919-4040</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="AsOf2024-11-18" id="Fact000017">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="AsOf2024-11-18" id="Fact000018">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="AsOf2024-11-18" id="Fact000019">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="AsOf2024-11-18" id="Fact000020">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="AsOf2024-11-18" id="Fact000021">Common     stock, $0.001 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="AsOf2024-11-18" id="Fact000022">GTBP</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="AsOf2024-11-18" id="Fact000023">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="AsOf2024-11-18" id="Fact000024">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
